- Home
- DIBS vs EDIT Comparison
DIBS vs EDIT Comparison
Compare DIBS & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIBS
- EDIT
- Stock Information
- Founded
- DIBS 2000
- EDIT 2013
- Country
- DIBS United States
- EDIT United States
- Employees
- DIBS N/A
- EDIT N/A
- Industry
- DIBS Catalog/Specialty Distribution
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DIBS Consumer Discretionary
- EDIT Health Care
- Exchange
- DIBS Nasdaq
- EDIT Nasdaq
- Market Cap
- DIBS 132.5M
- EDIT 108.1M
- IPO Year
- DIBS 2021
- EDIT 2016
- Fundamental
- Price
- DIBS $2.99
- EDIT $1.30
- Analyst Decision
- DIBS Hold
- EDIT Buy
- Analyst Count
- DIBS 1
- EDIT 14
- Target Price
- DIBS N/A
- EDIT $8.08
- AVG Volume (30 Days)
- DIBS 104.4K
- EDIT 2.9M
- Earning Date
- DIBS 05-07-2025
- EDIT 03-05-2025
- Dividend Yield
- DIBS N/A
- EDIT N/A
- EPS Growth
- DIBS N/A
- EDIT N/A
- EPS
- DIBS N/A
- EDIT N/A
- Revenue
- DIBS $88,257,000.00
- EDIT $32,314,000.00
- Revenue This Year
- DIBS $5.47
- EDIT N/A
- Revenue Next Year
- DIBS $6.46
- EDIT N/A
- P/E Ratio
- DIBS N/A
- EDIT N/A
- Revenue Growth
- DIBS 4.22
- EDIT N/A
- 52 Week Low
- DIBS $2.82
- EDIT $1.12
- 52 Week High
- DIBS $6.24
- EDIT $7.60
- Technical
- Relative Strength Index (RSI)
- DIBS 32.80
- EDIT 42.85
- Support Level
- DIBS $2.84
- EDIT $1.26
- Resistance Level
- DIBS $3.06
- EDIT $1.42
- Average True Range (ATR)
- DIBS 0.18
- EDIT 0.14
- MACD
- DIBS -0.02
- EDIT -0.04
- Stochastic Oscillator
- DIBS 20.99
- EDIT 5.26
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company's single reportable and operating segment contains two reporting units; 1stDibs, which consists of the company's online marketplace that enables commerce between sellers and buyers; and Design Manager, which is the company's separate online platform that is used to sell a software solution to interior designers. It generates revenue primarily from fees from seller marketplace services as well as other services, including advertisements and software services.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.